Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: March 2013

Chapter 7 - Drug dependence in headache patients

Summary

This chapter focuses on the psychiatric comorbidities of migraine and other headache disorders. Anxiety disorders have been found to be significantly associated with migraine in both clinical and community-based studies. Patients with migraine and tension-type headache exhibit psychiatric illnesses at a disproportionately higher rate than individuals with no history of recurrent headache. Unidirectional causal models suggest that an index disease increases the risk of the comorbid disorder. Psychiatric comorbidities can influence the frequency and severity of migraine, and impact disease prognosis, treatment, and clinical outcomes. Some psychiatric comorbidity, including depression and anxiety, has been associated with increasing migraine attack frequency, or progression from episodic to chronic migraine. Rates of psychiatric comorbidity are even higher among persons with more frequent headache. The high rates of psychiatric comorbidity with migraine highlights the importance for healthcare professionals (HCPs) to maintain diagnostic vigilance and provide appropriate treatment or referrals when necessary.

References

[1] EvansRW, BasinSM. Why migraineurs abuse butalbital-containing combination analgesics?Headache 2012; 50: 1194–7.
[2] FuhJL, WangSJ. Dependent behavior in patients with medication-overuse headache. Curr Pain Headache Rep 2012; 16: 73–9.
[3] ButlerSF, FernandezK, BenoitC, BudmanSH, JamisonRN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain 2008; 9: 360–72.
[4] Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine, 2001. (http://www.painmed.org/Workarea/DownloadAsset.aspx?id=3204)
[5] SilbersteinSD, OlesenJ, BousserMG, et al. (2005). The International Classification of Headache Disorders, 2nd edn (ICHD-II) – revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25(6): 460–5.
[6] TepperSJ, RothrockJF. Conclusions on opioids. Headache 2012; 52 Suppl 1: 38–9.
[7] SchneiderJP, KirshKL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J Opioid Managem 2010; 6: 385–95.
[8] OkieS. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981–5.
[9] SaperJR, LakeAE 3rd, BainPA, et al. A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring. Headache 2010; 50: 1175–93.
[10] Okie, S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363: 1981–5.
[11] NobleM, TreadwellJR, TregearSJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database of Syst Rev 2010, Issue 1.
[12] SaperJR, LakeAE. Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks and proposed guidelines. Headache 2008; 48: 838–49.
[13] EdlundMJ, MartinBC, FanMY, DevriesA, BradenJB, SullivanMD. Risks of opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend 2010; 112: 90–8.
[14] EdlundMJ, StefficD, HudsonT, HarrisKM, SullivanM. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007; 129: 355–62.
[15] LeeM, SilvermanSM, HansenH, PatelVB, ManchikantiL. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145–61.
[16] SaperJR, LakeAE 3rd, HamelRL, et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology. 2004; 62: 1687–94.
[17] CiceroTJ, WongG, TianY, LynseyM, TodorovA, IsenbergK. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from insurance claims database. Pain 2009; 144: 20–7.
[18] BuseDC, PearlmanSH, ReedML, SerranoD, Ng-MakDS, LiptonRB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012; 52: 18–36.
[19] RadatFR, Creac’hC, Guegan-MassardierE, et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache 2008; 48: 1026–36.
[20] BigalME, LiptonRB. Excessive opioid use and the development of chronic migraine. Pain 2009; 142: 179–82.
[21] BeckmannYY, SeckinM, ManavgatAI, ZorluN. Headaches related to psychoactive substance use. Clin Neurol Neurosurg 2012; epub ahead of print.
[22] LakeAE, SaperJR, HamelRL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache 2009; 49: 555–62.
[23] BuseDC, PearlmanSH, ReedML, SerranoD, Ng-MakDS, LiptonRB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012; 52: 18–36.
[24] ZieglerDK. Opioids in headache treatment. Is there a role?Neurol Clin 1997; 15: 199–207.
[25] SullivanMD, EdlundMJ, FanMY, DevriesA, Brennan BradenJ, MartinBC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: the TROUP study. Pain 2010; 150: 332–9.
[26] SullivanMD, EdlundMJ, SteffickD, UnutzerJ. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005; 119: 95–103.
[27] CiceroTJ, WongG, TianY, LynskeyM, TodorovA, IsenbergK. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain 2009; 144: 20–7.
[28] LakeAE, SaperJR, HamelRL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache 2009; 49: 555–62.
[29] ManchikantiL, GiordanoJ, BoswellMV, FellowsB, ManchukondaR, PampatiV. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Managem 2007; 3: 89–100.
[30] GalliF, PozziG, FrustaciA, et al. Differences in the personality profile of medication-overuse headache sufferers and drug-addict patients: a comparative study using MMPI-2. Headache 2011; 51: 1212–27.
[31] RadatF, IrachabalS, SwendsenJ, HenryP. Analgesic abuse and psychiatric comorbidity in headache patients. Encephale 2002; 28: 466–71.
[32] ZieglerDK. Opiate and opioid use in patients with refractory headache. Cephalalgia 1994; 14: 5–10.
[33] ButlerSF, BudmanSH, FernandezKC, et al. Development and validation of the current opioid misuse measure. Pain 2007; 103: 144–56.
[34] BrownJ, SetnikB, LeeK, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Managem 2011; 7: 467–83.
[35] JonesT, PassikSD. A comparison of methods of administering the opioid risk tool. J Opioid Managem 2001; 7: 347–51.
[36] BuelowA, HaggardR, GatchelRJ. Additional validation of the pain medication questionnaire in a heterogeneous sample of chronic pain patients. Pain Pract 2009; 9: 428–34.
[37] HojstedJ, NielsenPR, KendallS, FrichL, SjogrenP. Validation and usefulness of the Danish version of the pain medication questionnaire in opioid-treated chronic pain patients. Acta Anaesthesiol Scand 2011; 55: 1231–8.
[38] JonesT, MooreT, LevyJL, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain 2012; 28: 93–100.
[39] ButlerSF, BudmanSH, FanciulloGJ, JamisonRN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain 2010; 26: 770–6.
[40] MeltzerEC, RybinD, SaitzR, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain 2011; 152: 397–402.
[41] ChouR, FanciulloGJ, FinePG, MiaskowskiC, PassikSD, PortenoyRK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10: 131–46.
[42] GourlayDL, HeitHA, AlmahreziA, et al. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6: 107–12.
[43] RaffaRB. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther 2008; 33(2): 101–8.
[44] DesmeulesJA. The tramadol option. Eur J Pain 2000; 4: A15–21.
[45] RichterW, BarthH, FloheL, GiertzH. Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung 1985; 35: 1742–4.
[46] DesmeulesJA, PiquetV, CollartL, DayerP. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996; 41: 7–12.
[47] SenayEC, AdamsEH, GellerA, et al. Physical dependence on ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003; 69: 233–41.
[48] StoehrJD, EssaryAC, OuC, AshbyR, SucherM. The risk of tramadol abuse and dependence: findings from two patients. JAAPA 2009; 22: 31–2.
[49] FreyeE, LevyJ. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. Eur J Pain 2000; 4: 307–11.
[50] RobbinsL. Tramadol for tension-type headache. Headache 2004; 44: 192–3.
[51] AdamsEH, BreinerS, CiceroTJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Managem. 2006; 31: 465–76.
[52] InciardiJA, CiceroTJ, MunozA, et al. The diversion of ultram, ultracet, and generic tramadol HCL. J Addict Dis 2006; 25: 53–8.
[53] CiceroTJ, InciardiJA, AdamsEH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004. Pharmacoepidemiol Drug Saf. 2005; 14: 851–9.
[54] SkipperGE, FletcherC, Rocha-JuddR, BraseD. Tramadol abuse and dependence among physicians. JAMA 2004; 292: 1818–19.
[55] AdamsEH, DartRC, KniselyJS, SchnollSH. Tramadol abuse and dependence among physicians. JAMA 2005; 293: 1977–8.
[56] CiceroTJ, AdamsEH, GellerA, et al. A postmarketing surveillance program to monitor Ultram (trazodone hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7–22.
[57] TjaderbornM, JonssonAK, AhlnerJ, HaggS. Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf. 2009; 18: 1192–8.
[58] LoderE. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalalgia 2006; 26: 89–97.
[59] ParenteST, KimSS, FinchMD, et al. Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data. Am J Managm Care 2004; 10: 783–90.
[60] SilbersteinSD, McCroryDC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 2001; 41: 953–67.
[61] BigalME, BoruchoS, SerranD, LiptonRB. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 2009; 29: 891–7.
[62] RajaM, AltavistaMC, AzzoniA, AlbaneseA. Severe barbiturate withdrawal syndrome in migrainous patients. Headache 1996; 36: 119–21.
[63] SarrecchiaC, SordilloP, ConteG, RocchiG. Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication [article in Italian]. Ann Ital Med Int. 1998; 13: 237–9.
[64] BigalME, LiptonRB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71: 1821–8.
[65] BuckleyNA, McManusPR. Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983–1999). Drug Saf. 2004; 27: 135–41.
[66] CoupeySM. Barbiturates. Pediatr Rev 1997; 18: 260–4.
[67] SellersEM, Hoornweg, BustoUE, RomachMK. Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1996; 6: 18–25.
[68] FriedmanAP, DiSerioFJ. Symptomatic treatment of chronically recurring tension headache: a placebo-controlled, multicenter investigation of Fioricet and acetaminophen with codeine. Clin Ther 1987; 10: 69–81.
[69] KouyanouK, PitherCE, WesselyS. Medication misuse, abuse and dependence in chronic pain patients. J Psychosom Res 1997; 43: 497–504.
[70] HuffmanJC, SternTA. The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med 2003; 25: 427–37.
[71] LaderM. Benzodiazepines revisited – will we ever learn?Addiction. 2001; 106: 2086–109.
[72] NapchanU, BuseDC, LoderEW, et al. The use of marijuana or synthetic cannabinoids for the treatment of headache. Headache: J Head Face Pain 51: 502–5.
[73] Martín-SánchezE, FurukawaTA, TaylorJ, et al. (2009). Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 10: 1353–68.
[74] FeinsteinAR, HeinemannLA, DalessioD, et al. Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68: 457–67.
[75] MittenbergW, PattonC, CanyockEM, ConditDC. Base rates of malingering and symptoms exaggeration. J Clin Exp Neuropsychol 2002; 24: 1094–102.
[76] FishbainDA, CutlerR, RosomoffHL, RosomoffRS. Chronic pain disability exaggeration/malingering and submaximal effort research. Clin J Pain 1999; 15: 244–74.
[77] AronoffGM, MandelS, GenoveseE, et al. Evaluating malingering in contested injury or illness. Pain Pract 2007; 7: 178–204.
[78] NicholsonK, MartelliMF. The problem of pain. J Head Trauma Rehabil 2004; 19: 2–9.
[79] EvansRW. Persistent post-traumatic headache, postconcussion syndrome, and whiplash injuries: the evidence for a non traumatic basis with an historical review. Headache 2010; 50: 716–24.
[80] GroverCA, CloseRJ, WieleED, VillarrealK, GoldmanLM. Quantifying drug-seeking behavior: a case control study. J Emerg Med 2012; 42: 15–21.
[81] HopwoodCJ, OrlandoMJ, ClarkTS. The detection of malingered pain-related disability with the Personality Assessment Inventory. Rehabil Psychol 2010; 55: 307–10.
[82] RogersR, GillardND, WooleyCN, RossCA. The detection of feigned disabilities: the effectiviness of the personality assessment inventory in a traumatized inpatient sample. Assessment 2012; 19: 77–88.
[83] SellbomM, ToomeyJA, WygantDB, KucharskiLT, DuncanS. Utility of the MMPI-2-RF (Restructured Form) validity scales in detecting malingering in a criminal forensic setting: a known-groups design. Psychol Assessm 2010; 22: 22–31.
[84] McCarbergBH. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrand Med 2011; 123: 124–31.
[85] HawkinsSC, SmeesF, HamelJ. Emergency management of chronic pain and drug-seeking behavior: an alternate perspective. J Emerg Med 2008; 34: 125–9.